Scholar Rock
Novel biopharmaceutical therapeutics targeting protein signaling pathways
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2012
- Latest Form D
- $36.3M, Jan 2016
- Total capital
- $36.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $36.3M
- 1 Form D · last Jan 2016
- 130 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 19
- 21 pending · first 2022
- Rank in peer group#53 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$36.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#53 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Amir NashatDirectorNamed in SEC Form D filings
- Katrine BosleyDirectorNamed in SEC Form D filings
- Kristina BurowDirectorNamed in SEC Form D filings
- Michael GilmanDirectorNamed in SEC Form D filings
- Nagesh MahanthappaExecutive Officer, DirectorNamed in SEC Form D filings
- Timothy SpringerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 19 granted of 40- New patentTGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOFUSPTOUS 12,753,226
- PendingMethods For Inhibiting Myostatin Activation By Administering Anti-pro/latent Myostatin AntibodiesUSPTOApplication 19427341
- PendingLtbp Complex-specific Inhibitors Of Tgf-beta 1 And Uses ThereofUSPTOApplication 19235027
Show all 40 patent records
- TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOFOct 6, 2026 · US 12,753,226Granted
- Methods For Inhibiting Myostatin Activation By Administering Anti-pro/latent Myostatin AntibodiesAug 20, 2026 · Application 19427341Pending
- Ltbp Complex-specific Inhibitors Of Tgf-beta 1 And Uses ThereofAug 13, 2026 · Application 19235027Pending
- Methods of Treating Myopathies with Anti-Pro/Latent Myostatin AntibodiesJun 23, 2026 · US 12,661,400Granted
- Compositions And Methods For Growth Factor ModulationApr 23, 2026 · Application 19335639Pending
- Method of Making Anti-Pro/Latent Myostatin AntibodiesMar 24, 2026 · US 12,582,712Granted
- Compositions And Methods For Growth Factor ModulationMar 17, 2026 · US 12,577,296Granted
- Selective And Potent Inhibitory Antibodies Of Myostatin ActivationFeb 5, 2026 · Application 19212099Pending
- Methods For Treating Metabolic Diseases By Inhibiting Myostatin ActivationFeb 5, 2026 · Application 19083831Pending
- Compositions And Methods For Growth Factor ModulationOct 28, 2025 · US 12,454,570Granted
- Use Of Myostatin Inhibitor For Treating Spinal Muscular AtrophyOct 23, 2025 · Application 18862079Pending
- Rgmc-selective Inhibitors And Use ThereofOct 2, 2025 · Application 19178027Pending
- Tgf-beta Inhibitors And Use ThereofSep 11, 2025 · Application 18283904Pending
- HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOFAug 14, 2025 · Application 19045513Pending
- Ltbp Complex-specific Inhibitors Of Tgf-beta 1 And Uses ThereofJul 15, 2025 · US 12,358,992Granted
- Isoform-selective TGFB1 Inhibitors And Use ThereofJul 3, 2025 · Application 18887382Pending
- Selective And Potent Inhibitory Antibodies Of Myostatin ActivationJun 24, 2025 · US 12,338,279Granted
- LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOFJun 5, 2025 · Application 18941156Pending
- Rgmc-selective Inhibitors And Use ThereofMay 13, 2025 · US 12,297,262Granted
- TGFBeta Antibodies, Methods and UsesApr 22, 2025 · US 12,281,159Granted
- METHODS OF SCREENING FOR HIGH-AFFINITY, ISOFORM- SELECTIVE TGFb1 INHIBITORSMar 18, 2025 · US 12,252,531Granted
- LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOFDec 24, 2024 · US 12,173,059Granted
- Methods For Inhibiting Myostatin Activation By Administering Anti-pro/latent Myostatin AntibodiesNov 28, 2024 · Application 18646693Pending
- A Myostatin Pathway Inhibitor In Combination With A GLP-1 Pathway Activator For Use In Treating Metabolic DisordersNov 7, 2024 · Application 18572397Pending
- Isoform-selective TGFB1 Inhibitors And Use ThereofOct 22, 2024 · US 12,122,823Granted
- LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOFSep 12, 2024 · Application 18578341Pending
- Tgf-beta Inhibitors And Therapeutic Use ThereofSep 5, 2024 · Application 18566054Pending
- Methods For Altering Body Composition By Administering Anti-pro/latent Myostatin AntibodiesJun 11, 2024 · US 12,006,359Granted
- Compositions for Making and Using Anti-Myostatin AntibodiesMar 12, 2024 · US 11,925,683Granted
- Isoform-specific, Context-permissive TGFB1 Inhibitors And Use ThereofJan 18, 2024 · Application 18363435Pending
- Use Of Anti-pro/latent Myostatin Antibody For Treating Spinal Muscular AtrophyJan 4, 2024 · Application 18250489Pending
- Compositions And Methods For Growth Factor ModulationNov 28, 2023 · US 11,827,698Granted
- TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOFNov 2, 2023 · Application 18193979Pending
- TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOFMay 9, 2023 · US 11,643,459Granted
- Tgfb Inhibitors And Use ThereofFeb 23, 2023 · Application 17791859Pending
- Tgf-beta Inhibitors And Use ThereofFeb 16, 2023 · Application 17758524Pending
- Methods for Using Anti-Myostatin AntibodiesSep 13, 2022 · US 11,439,704Granted
- LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOFJun 21, 2022 · US 11,365,245Granted
- Methods For Treating Metabolic Diseases By Inhibiting Myostatin ActivationApr 7, 2022 · Application 17448389Pending
- LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOFJan 4, 2022 · US 11,214,614Granted
Related companies, and why
- Liquid BioScience, Inc.Similar federal contract value in Biotech · null in contracts
- Earli Inc.Similar federal contract value in Biotech · null in contracts
- Bugworks Research, Inc.Similar federal contract value in Biotech · null in contracts
- SeaStar Medical, Inc.Similar federal contract value in Biotech · null in contracts
- SynthorxSimilar federal contract value in Biotech · null in contracts
- Contineum TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .